fda warning bpc 157 safety concerns Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling Five reasons adding peptides to
Description
Your savings have been added to the cart

10.22203/ecm.v029a06 10 BhattaraiN.GunnJ.ZhangM

518 Studies indicate that liraglutide may inhibit liver carcinogenesis through its metabolic effects, suggesting that GLP-1RAs could potentially play a role in preventing or managing HCC in the context of NASH

Should it receive approval, this application would set the drug up to be used in the same cases as Wegovy
